Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in…

By W. Sikov, D. Berry, Charles M. Perou, Baljit Singh, C. Cirrincione, S. Tolaney, C. Kuzma, T. Pluard, G. Somlo, E. Port and 7 more. Journal of Clinical Oncology, 2015

867 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/286ecca68d07480f10b8bf4e50d305b00a9bfebd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Lisa A. Carey

In Oncology

1. J. Baselga
2. Yongheng Chen
3. S. Leonov
4. Huajun Zhang
5. Lin Chen
6. Na Liu
7. Masakazu Toi
8. Yun R Li

Citations in the corpus

• An overview of triple-negative breast cancer (2016, background): “role of carboplatin could be evaluated in definitive future studies, ideally limited to biologically defined patient subsets most likely to benefit from this agent [129].”
• Recent advances in therapeutic strategies for triple-negative breast cancer (2022, methodology): “For patients with stages II to III TNBC, a phase II trial (NCT00861705) aimed to evaluate carboplatin and/or bevacizumab on pCR after neoadjuvant therapy (paclitaxel followed by doxorubicin and cyclophosphamide) [29].”
• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018, background): “Neoadjuvant therapy: Chemotherapy The inclusion of carboplatin with anthracycline- and taxane-based chemotherapy improved the rate of pathologic complete response (pCR) in triple negative breast cancer (TNBC) and translated into disease-free survival benefit though the role for such treatment when p”
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, background): “Neoadjuvant systemic therapies An improved pCR rate was observed with carboplatin for patients with triple-negative disease [75, 76].”